Downloaded 79 times
Uploaded byVadivel Kumaran Sivasankaran
PPI when and where
PPI's work by inhibiting gastric H+K+-ATPase and decreasing acid secretion. They are indicated for peptic ulcer disease, gastroesophageal reflux disease, and other acid-related conditions. Common side effects include diarrhea and headache. Long-term PPI use has been associated with nutrient deficiencies, increased risk of fractures, community-acquired pneumonia, and small intestinal bacterial overgrowth. PPIs also interact with some drugs by affecting CYP enzyme metabolism.
More Related Content
Similar to PPI when and where
More from Vadivel Kumaran Sivasankaran
PPI when and where
- 1. PPI’S – ANOVERVIEW DR S.VADIVEL KUARAN CONSULTANT MEDICAL GASTROENTEROLOGIST AND HEPATOLOGIST KAUVERY HOSPITAL,ALWARPET CHENNAI
- 4. INTRODUCTION • Decrease gastricacid secretion by inhibiting gastric H⁺K⁺-ATPase . • Omeprazole first PPI- 1989. • PPI’s are weak bases that concentrate in acidic spaces with pKa1- 3-8 to 4.5.
- 5. • PPI’s aremetabolised by CYP2C19 and CYP3A4. • Rabeprazole has higher affinity for CYP3A4. • Conc. of PPI in secretory canaliculus is 100000 to 1000000 higher than in blood. • All PPI bind to cysteine 813. • Omeprazole- cysteine 892 Lansoprazole- cysteine 321 Pantoprazole – cysteine 822
- 6. INDICATIONS • PEPTIC ULCERDISEASE • TREATMENT AND PREVENTION OF GASTRODUODENAL ULCERS DUE TO NASAID. • ERADICATION OF H.PYLORI • ZOLLINGER ELLISON SYNDROME • BARRETT’S METAPLASIA • GASTROESOPHAGEAL REFLUX DISEASE • ESOPHAGEAL STRICTURES • EXTRAESOPHAGEAL MANIFESTATIONS
- 7. pKa?? • It refersto degree of willingness of compoud to accept or donate a proton. • Compound with pKa of 5 is 10 fold more basic than compound with pKa of 4.
- 10.
- 11. GASTRIC H⁺K-ATPase • Foundin parietal cells and small amounts in renal medulla. • It has α and β subunits. • 3 types F, V1, P1 and P2.
- 15. COMMON SIDE EFFECTS •2812 pts on OMEPRAZOLE Headache(2.4%) Diarrhea (1.9%) Nausea(0.9%) Rash( 1.1%) • 5669 pts on Lansoprazole Diarrhea(4.1%) Headache(2.9%). Nausea( 2.6%)
- 16. ADVERSE EFFECTS • PhysiologicalHypergastrinemia • Fundic gland Polyposis • Drug interactions • Vit B12 metabolism and pernicious anemia • Osteopenia and osteoporosis • Community acquired pneumonia • Bacterial overgrowth
- 17. HYPERGASTRINEMIA • PPI’s causephysiological hypergastrinemia. • Hypergastrinemia causing ECL Hyperplasia is controversial. • Only one published report of ECL Hyperplasia and gastric malignancy in ZES pt treated with high dose PPI.
- 18. FUNDIC GLAND POLYPOSIS(FGP) •PPI use leads to 4 fold risk of Fundic gland polyposis. • H.pylori also increases risk of FGP. • Eradication of H.pylori or stopping PPI leads to regression of polyposis. • It doesn’t lead to Adenocarcinoma.
- 19. DRUG INTERACTIONS • AllPPI’s metabolized by CYP2C19 except Rabeprazole high affinity for CYP3A4. • Reduce absorption and bioavailability of ketoconazole, Itraconazole and sucralfate. • All PPI’s except Pantoprazole affect the effectiveness of clopidogrel- 40% risk of coronary stent occlusion.
- 20. IRON & B12 •To small extent affect iron absorption. • Elderly and ZES pts on high dose PPI have reduced B12 concentration.
- 21. PPI and Metabolicbone disease??? • PPI > 5 yrs risk of osteoporosis by 1.62 fold • PPI > 7 yrs risk of osteoporosis by 4.55 fold. • Rarely osteoporotic fractures reported even with 6- 12 months of high dose PPI.
- 22. CAP • PPI useleads to bacterial colonization of stomach and pulmonary micro aspirations. • Odd’s ratio is 1.89 for current PPI use , 1.55 for past PPI use. • On contrary PPI do not increase risk of HAP.
- 23. PPI & SIBO?? •PPI postulated as one of etiological factor for SIBO due to reduced acid provacating bacterial colonization of GIT. • Clostridium difficile infection.
- 24.
- 27.
- 28. Trials favouring Gastros •PLATO TRIAL • COGENT TRIAL • TRITON TRIAL
- 30. ADD PPI- PANTO/RABE/LANSO/DEXLANSO ANY OFFOLLOWING ADVANCED AGE/ H.PYLORI/ NSAID USE YES NO PATIENT TAKING CLOPIDOGREL HISTORY OF GI BLEED
- 31. NOVEL STRATEGIES • TENATOPRAZOLE •DEXLANSOPRAZOLE MR • “VECAM”
- 32. TAKE HOME MESSAGE •PPI TO BE ADMINISTERED 30 MIN BEFORE BREAKFAST. • TWICE DOSAGE FOR MAXIMAL ACID SUPPRESSION. • RABEPRAZOLE ACID LABILE, RAPID ONSET OF ACTION. • RATIONALIZE CONCOMITANT USE OF PPI AND ANTIPLATELETS. • RCT’S – OMEPRAZOLE & ESOMEPRAZOLE MORE INTERACTIONS WITH ANTIPLATELETS